Hyperoside attenuates diabetic nephropathy by activating the Nrf2/SLC7A11/GPX4 axis to restrain ferroptosis

Figure 3 Hyperoside confers protection against erastin-induced ferroptotic injury. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.001. One-way analysis of variance + Tukey’s post hoc test; two-sided. Data are expressed as the mean ± SD; n = 3 independent experiments. A: Cell Counting Kit-8 times course (0-48 hours): Control, erastin (5 μM), and hyperoside (50 μM) + erastin; B: Lactate dehydrogenase, malondialdehyde, Fe²⁺, and glutathione; C: Lipid reactive oxygen species; D: Terminal deoxynucleotidyl transferase dUTP nick-end labeling apoptosis; E: Western blot of Nrf2, SLC7A11, and GPX4. LDH: Lactate dehydrogenase; MAD: Malondialdehyde; OD: Optical density; GSH: Glutathione; FITC-A: Fluorescein isothiocyanate-area; DAPI: 4’,6-diamidino-2-phenylindole; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick-end labeling.